within Pharmacolibrary.Drugs.ATC.L;

model L04AC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.119 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0.00484,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Basiliximab is a chimeric monoclonal antibody that acts as an interleukin-2 (IL-2) receptor antagonist. It is primarily used for the prophylaxis of acute organ rejection in patients undergoing renal transplantation, in combination with other immunosuppressive agents. Basiliximab is currently approved and in use for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult renal transplant recipients after intravenous administration, as summarized in multiple studies.</p><h4>References</h4><ol><li><p>Onrust, SV, &amp; Wiseman, LR (1999). Basiliximab. <i>Drugs</i> 57(2) 207–214. DOI:<a href=&quot;https://doi.org/10.2165/00003495-199957020-00006&quot;>10.2165/00003495-199957020-00006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/10188761/&quot;>https://pubmed.ncbi.nlm.nih.gov/10188761</a></p></li><li><p>Podichetty, JT, et al., &amp; Kiel, PJ (2020). Pharmacokinetics of Basiliximab for the Prevention of Graft-versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplantation with Minimal-Intensity Cyclophosphamide and Fludarabine. <i>Pharmacotherapy</i> 40(1) 26–32. DOI:<a href=&quot;https://doi.org/10.1002/phar.2347&quot;>10.1002/phar.2347</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31742732/&quot;>https://pubmed.ncbi.nlm.nih.gov/31742732</a></p></li><li><p>McKeage, K, &amp; McCormack, PL (2010). Basiliximab: a review of its use as induction therapy in renal transplantation. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 24(1) 55–76. DOI:<a href=&quot;https://doi.org/10.2165/11203990-000000000-00000&quot;>10.2165/11203990-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20055533/&quot;>https://pubmed.ncbi.nlm.nih.gov/20055533</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AC02;
